PFE | Weekly | Haru Insights

A Delaware federal judge denied Pfizer’s motion to dismiss a patent infringement lawsuit brought by Bayer’s Monsanto unit over mRNA technology used in its COVID-19 vaccines—a pivotal legal reversal that threatens the foundation of Pfizer’s post-pandemic mRNA growth strategy.
Pfizer reported Q2 revenue of $15.03 billion, surpassing estimates and driving a 14.8% stock surge, though it missed full-year EPS guidance, highlighting persistent execution concerns despite strong top-line performance.

Tilrekimig’s Phase 2 triumph—delivering over 60% EASI-75 responses—signals a breakthrough in atopic dermatitis care and positions Pfizer for a blockbuster in chronic inflammatory diseases with transformative commercial potential.
The strategic Metsera acquisition and berobenatide’s Phase III advancement mark a bold, well-timed entry into the booming oral GLP-1 market, putting Pfizer on a credible path to disrupt injectable giants like Eli Lilly and Novo Nordisk.
The deepened AI partnership with Boltz introduces a game-changing R&D model capable of accelerating drug discovery, reducing time-to-market, and securing a durable innovation edge in an era where speed equals survival.
Seagen’s integration and a robust oncology pipeline, including 45 ESMO abstracts and advanced candidates like atirmociclib and tivunatamig, affirm Pfizer’s growth ambitions in immuno-oncology and elevate its standing among elite cancer drug developers.
Inclusion in the 340B Rebate Model Pilot represents a major institutional validation of Pfizer’s role in safety-net healthcare, potentially unlocking long-term pricing stability and regulatory clarity despite ongoing political volatility.

Pfizer Inc. (PFE)[Tv]